PRESS RELEASE: Minerva Imaging acquires BioAdvice
As of November 1, 2019, Minerva Imaging ApS has acquired BioAdvice A/S. Minerva Imaging will focus on securing the continued operation of BioAdvice and will further strengthen the capabilities and services of the company.
The combined businesses of Minerva Imaging and BioAdvice will consist of almost 30 employees, including 10 scientists and veterinarians and offer a strong combination of contract research opportunities for our collaborators and stakeholders. During the coming year, Minerva Imaging will upgrade part of the BioAdvice property in Oelstykke and relocate its primary business operations to the new facility of BioAdvice.
Carsten Nielsen, CEO and Co-founder at Minerva Imaging: “It is a very exciting time for Minerva Imaging and BioAdvice. We are looking forward to further expand and develop our capabilities while continuously delivering high-quality studies to our clients”.
About BioAdvice A/S
BioAdvice is a GLP and GMP compliant CRO founded in 1999. BioAdvice has thorough experience within pharmacological drug testing, including batch release testing and medical device testing. Our services include drug testing in rodents and large animal species increasing the translational value in metabolism, inflammation and dermatology. Our competences have been built on many years of experience within the field and a close collaboration with our customers and the authorities.
About Minerva Imaging ApS
Minerva Imaging is a scientifically driven CRO founded in 2011. Our focus is on the use of advanced oncology models and molecular imaging for translational cancer research and drug development. We engage with our clients to understand their scientific questions and discuss how our methods and capabilities can provide answers. Our competences build on more than two decades of research within oncology, cardiovascular disease and molecular imaging performed at the University of Copenhagen and Rigshospitalet, the National University Hospital of Denmark.
Please contact us for further information.